Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 556 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thrombosis, Venous Clear all
Not listed Phase 4 Interventional

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

NCT04169269
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters, Rivaroxaban 10 milligram Oral Tablet
Drug
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders

NCT00071227
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion
Interventions
Triamcinolone Acetonide (TAC-PF)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 11:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Factors for Venous Thromboembolism

NCT00018772
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

OsciPulse Device for the Prevention of VTE

NCT04625673
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Thromboembolisms
Interventions
OsciPulse
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 30, 2026, 11:22 AM EDT
Terminated Not applicable Interventional

The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots

NCT00580424
View directory record Official record
Conditions
Women's Health, Blood Coagulation Disorders
Interventions
Norethindrone
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Oct 30, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia

NCT03195010
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematologic and Lymphocytic Disorder, Hematopoietic Cell Transplantation Recipient, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis, T-Cell Non-Hodgkin Lymphoma, Thrombocytopenia, Venous Thromboembolism
Interventions
Platelet Transfusion
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

NCT00493064
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Nicotinic acid, Prednisolone acetate
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Not applicable Interventional

Single Comprehensive Ultrasound to Rule Out DVT in High-risk Patients

NCT00333697
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Comprehensive Duplex Ultrasound (diagnostic study)
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2011 · Synced Oct 30, 2026, 11:22 AM EDT
Completed No phase listed Observational

Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data

NCT04735523
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
5,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 11:22 AM EDT
Terminated Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

NCT00714597
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713
View directory record Official record
Conditions
Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis, Hepatic Thrombosis, Malignant Neoplasm, Mesenteric Thrombosis, Metastatic Malignant Neoplasm, Portal Vein Thrombosis, Pulmonary Embolism, Renal Vein Thrombosis, Splenic Thrombosis, Venous Thromboembolism
Interventions
Apixaban, Dalteparin, Questionnaire Administration
Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
18
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Evanston, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 30, 2026, 11:22 AM EDT
Terminated Phase 3 Interventional Results available

Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism

NCT00423683
View directory record Official record
Conditions
Cancer, Thromboembolism
Interventions
Arixtra alone, Arixtra + filter
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2007 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972
View directory record Official record
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 3 Interventional

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

NCT00182143
View directory record Official record
Conditions
Critical Illness, Deep Venous Thrombosis
Interventions
LMWH (Fragmin, dalteparin), Unfractionated Heparin
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
3,659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Rochester, Minnesota • St Louis, Missouri • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

NCT00322270
View directory record Official record
Conditions
Thrombosis, Venous Thrombosis, Catheter Occlusion
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Casa Grande, Arizona • Soquel, California • Boynton Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2008 · Synced Oct 30, 2026, 11:22 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

NCT00211354
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Not applicable Interventional

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

NCT00334464
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Standard of care or genotyping dosing of warfarin dosing
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 30, 2026, 11:22 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

NCT01029821
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Low-Molecular-Weight Heparin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 30, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 11:22 AM EDT
Completed No phase listed Observational

Predictors of Anticoagulation Control on Warfarin Therapy

NCT00905177
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Heart Valve Replacement
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 30, 2026, 11:22 AM EDT
Terminated No phase listed Observational

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

NCT01875770
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 30, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 30, 2026, 11:22 AM EDT